Vertex Holdings Appoints Temasek CEO Dilhan Pillay Sandrasegara as Chairman Amid Record Profits and IPO Momentum

Singapore-based Vertex Holdings has appointed Dilhan Pillay Sandrasegara, Executive Director and CEO of Temasek Holdings, as its new Chairman effective April 15, 2026.

This leadership change marks the next phase of Vertex's transformation, aiming for greater synergy with Temasek's funding platforms.

Seamless Leadership Transition

Outgoing Chairman Teo Ming Kian and Deputy Chairman Lee Kheng Nam will retire from the board.

The board plans to review its composition to maintain strong governance and diverse international perspectives.

Robust Financial Performance in FY2025

Vertex reported a profit exceeding $100 million for the financial year ended FY2025, driven by strong portfolio performance.

Key private market exits included EyeBio's acquisition by Merck for up to $3 billion, Salesforce's purchase of Own Company for $2.1 billion, and others totaling significant value realizations.

In public markets, Horizon Robotics listed at $6.7 billion in 2024 and grew to approximately $13 billion by early April 2026, with Vertex retaining shares.

Promising Future and Global Expansion

Early 2026 saw Edge Medical's Hong Kong listing at $2 billion, Cymbio's sale to PayPal for $160 million, and XConn's acquisition by Marvell for $540 million.

SpyGlass Pharma completed its Nasdaq IPO in February 2026, highlighting momentum in healthcare investments.

At least five portfolio companies are advancing toward public listings on major exchanges like Nasdaq, NYSE, and HKEX over the next 12 months.

Sandrasegara's prior role on Vertex's board from 2015-2018 and oversight during Temasek's Enterprise Development Group position him to drive further innovation.

With nearly $7 billion in assets under management across Southeast Asia, India, China, Israel, the US, Korea, and Japan, Vertex is poised for increased distributions and growth.